home / stock / sprb / sprb quote
Last: | $0.7721 |
---|---|
Change Percent: | 2.37% |
Open: | $0.7375 |
Close: | $0.7542 |
High: | $0.777 |
Low: | $0.73 |
Volume: | 246,103 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.7721 | $0.7375 | $0.7542 | $0.777 | $0.73 | 246,103 | 05-07-2024 |
$0.7542 | $0.75 | $0.7542 | $0.756 | $0.7251 | 340,888 | 05-06-2024 |
$0.7444 | $0.755 | $0.7444 | $0.7572 | $0.7329 | 503,654 | 05-03-2024 |
$0.7416 | $0.73 | $0.7416 | $0.7499 | $0.7209 | 280,082 | 05-02-2024 |
$0.7174 | $0.73 | $0.7174 | $0.7507 | $0.7101 | 750,778 | 05-01-2024 |
$0.708 | $0.7 | $0.708 | $0.7187 | $0.7 | 243,404 | 04-30-2024 |
$0.71 | $0.7073 | $0.71 | $0.7167 | $0.69 | 255,561 | 04-29-2024 |
$0.7 | $0.71 | $0.7 | $0.710101 | $0.6977 | 211,577 | 04-26-2024 |
$0.701 | $0.6802 | $0.701 | $0.7104 | $0.6802 | 379,744 | 04-25-2024 |
$0.7018 | $0.69 | $0.7018 | $0.7127 | $0.6894 | 417,901 | 04-24-2024 |
$0.7012 | $0.6956 | $0.7012 | $0.7488 | $0.6956 | 1,022,240 | 04-23-2024 |
$0.692 | $0.68 | $0.692 | $0.7029 | $0.6711 | 458,952 | 04-22-2024 |
$0.7004 | $0.7 | $0.7004 | $0.7112 | $0.6873 | 663,290 | 04-19-2024 |
$0.701 | $0.693 | $0.701 | $0.716 | $0.693 | 311,619 | 04-18-2024 |
$0.7062 | $0.693 | $0.7062 | $0.74 | $0.693 | 707,703 | 04-17-2024 |
$0.7002 | $0.6901 | $0.7002 | $0.7386 | $0.6873 | 861,965 | 04-16-2024 |
$0.7057 | $0.7396 | $0.7057 | $0.7398 | $0.6832 | 1,277,676 | 04-15-2024 |
$0.7362 | $0.7733 | $0.7362 | $0.7733 | $0.731 | 521,794 | 04-12-2024 |
$0.7635 | $0.7499 | $0.7635 | $0.7805 | $0.741 | 426,233 | 04-11-2024 |
$0.7498 | $0.78 | $0.7498 | $0.78 | $0.7388 | 732,149 | 04-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH) The company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a po...
Presentation to highlight baseline characteristics of Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-s...
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b st...